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Abstract: OBJECT Data on health-related costs after aneurysmal subarachnoid hemorrhage (aSAH)
are limited. The aim was to evaluate outcome, return to work and costs after aSAH with focus on
differences between high- and low-grade aSAH (defined as World Federation of Neurological Surgeons
[WFNS] grades 4-5 and WFNS 1-3, respectively). METHODS A cross-sectional study was performed,
including all consecutive survivors of aSAH over a 4-year period. A telephone interview was conducted
to assess the Glasgow Outcome Scale Extended and employment status before and after aSAH. Direct
costs were calculated by multiplying the length of hospitalization by the average daily costs. Indirect
costs were calculated for productivity losses until retirement age according to the human capital approach.
RESULTS Follow-up was performed 2.7 years after aSAH (range 1.3-4.6). Favorable outcome was achieved
in 114 of 150 patients (76%) and work recovery in 61 of 98 patients (62%) employed prior to aSAH. High-
grade compared to low-grade aSAH resulted less frequently in favorable outcome (52% vs. 85%; p < 0.001)
and work recovery (39% vs. 69%; p = 0.013). The total costs were € 344.277 (95% CI 268.383-420.171)
per patient, mainly accounted to indirect costs (84%). The total costs increased with increasing degree
of disability and were greater for high-grade compared to low-grade aSAH (€ 422.496 vs. € 329.193; p
= 0.039). The effective costs per patient with favorable outcome were 2.1-fold greater for high-grade
compared to low-grade aSAH (€ 308.625 vs. € 134.700). CONCLUSION Favorable outcome can be
achieved in a considerable proportion of high-grade aSAH patients, but costs are greater compared to
low-grade aSAH. Further cost-effectiveness studies in the current era of aSAH management are needed.
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Object: Data on health-related costs after aneurysmal subarachnoid hemorrhage (aSAH) are 
limited. The aim was to evaluate outcome, return to work and costs after aSAH with focus on 
differences between high- and low-grade aSAH (defined as World Federation of Neurological 
Surgeons (WFNS) grades 4-5 and WFNS 1-3, respectively). 
 
Methods: A cross-sectional study was performed, including all consecutive survivors of aSAH 
over a 4-year period. A telephone interview was conducted to assess the Glasgow Outcome 
Scale Extended (GOSE) and employment status before and after aSAH. Direct costs were 
calculated by multiplying the length of hospitalization by the average daily costs. Indirect costs 
were calculated for productivity losses according to the human capital approach. 
 
 Results: Follow-up was performed 2.7 years after aSAH (range 1.3- 4.6). Favorable outcome 
was achieved in 114 of 150 patients (76%) and work recovery in 61 of 98 patients (62%) 
employed prior to aSAH. High-grade compared to low-grade aSAH resulted less frequently in 
favorable outcome (52% versus 85%; p<0.001) and work recovery (39% versus 69%; p=0.013). 
The total costs were € 344.277 (95% CI 268.383 – 420.171) per patient, mainly accounted to 
indirect costs (84%). The total costs increased with increasing degree of disability and were 
greater for high-grade compared to low-grade aSAH (€ 422.496 versus € 329.193; p=0.039). 
The effective costs per patient with favorable outcome were 2.1-fold greater for high-grade 
compared to low-grade aSAH (€ 308.625 versus € 134.700).  
 
Conclusion: Favorable outcome can be achieved in a considerable proportion of high-grade 
aSAH patients, but health-related costs are greater compared to low-grade aSAH. Further cost-
effectiveness studies in the current era of aSAH management are needed.  
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INTRODUCTION 
Improved aneurysm treatment modalities and advances in neurocritical care have resulted in a 
paradigm shift over the past decades with regards to treatment options and potentially good 
prognosis after high-grade aneurysmal subarachnoid hemorrhage (aSAH), defined as World 
Federation of Neurosurgical Societies (WFNS) grades 4 and 5 1,2. In recent studies, the authors 
have suggested that early aneurysm treatment in combination with neurocritical care can result 
in functional independence in more than half of the patients with high-grade aSAH 3,4. 
However, high-grade aSAH patients have a long-term ICU-stay aiming to prevent secondary 
brain injuries, and in many cases also require long-term rehabilitation programs to achieve the 
best possible functional outcome.  
 
To date, there are only few health economic evaluations estimating the contemporary costs in 
the current era of aSAH management 5,6. The economic costs of aSAH in the United Kingdom 
have been estimated at £ 510 million in 2005 including the costs from in-hospital treatment 
which account for 59% of the total costs 7. A German study reported that costs per patient were 
€ 38.300 within the first year after aSAH, of which 59% resulted from acute in-hospital 
treatment and 41% from productivity losses due to failure to return to work 8. Further insights 
on healthcare costs with regards to functional recovery and working capacity are important to 
assess the effectiveness of aSAH management today.  
 
The aim of the study was to investigate outcome, return to work and costs after aSAH in a 
cohort of consecutive aSAH survivors treated at a single center in Switzerland with the focus 







The patients were selected from a prospective database of consecutive aSAH patients, treated 
between January 2007 and August 2010 at the Neurocritical Care Unit, University Hospital 
Zurich, Switzerland. All patients were treated according to a standardized treatment protocol 
including early aneurysm occlusion (within 24-48 hours) using surgical clipping or 
endovascular coiling after interdisciplinary discussion and maximal neurocritical care including 
barbiturate coma and therapeutic hypothermia as a last resort therapy option in patients with 
high intracranial pressure and/or delayed cerebral ischemia refractory to conventional treatment 
9,10. Patients deceased or living abroad were excluded from the study. All other patients were 
invited by mail to participate in a structured telephone interview about their neurological 
recovery and employment status. Patients were excluded if informed consent could not be 
obtained from the patient or their legal representative. A flow chart of the patients included in 
the study is presented in Figure 1. The study protocol was approved by the local ethics 
committee of the University Zurich, Switzerland (Ref. Nr. EK: KEK-ZH-Nr. 2011-0429).  
 
Patient Characteristics  
The following data from the prospective institutional database were analyzed: age at time of 
aSAH, gender, WFNS score, Fisher grade, aneurysm location, type of aneurysm treatment, and 
Glasgow Outcome Score (GOS) at 3 and 12 months after aSAH. The severity of aSAH was 
classified as low-grade in patients with WFNS scores 1-3 or high-grade in patients with WFNS 
score 4-5. The length of stay in the neurocritical care unit, neurosurgical ward and rehabilitation 





Telephone Interview About Functional Outcome and Return to Work 
In August 2011, a single investigator (D.O.) conducted a structured telephone interview to 
assess outcome and employment status. Standardized questionnaires for assessment of the 
Glasgow Outcome Scale (GOS) and Glasgow Outcome Scale-Extended (GOSE) were used to 
measure the level of disability and dependence as previously reported 11. Key features of both 
outcome scales are presented in Table 1. Questions on work recovery were adapted from a 
previous study on return to work after aSAH 12. Return to work was defined as the resumption 
of productive activities and assessed by asking the patients about the type of job and workload 
(percentage of weekly working hours) before and after aSAH. In case of incomplete recovery, 
the patients were asked to report their complaints. The responses of patients were categorized 
into (1) complete work recovery, (2) incomplete work recovery, (3) failure to return to work 
due to health problems related to aSAH, or (4) early retirement after aSAH.  
 
Health-Related Costs 
Health-related costs were calculated for the period between the day of aSAH and follow-up. 
The total costs included costs for inpatient care (direct costs) as well as productivity losses due 
to problems related to aSAH (indirect costs). Direct costs were based on the average daily 
hospital and rehabilitation costs derived from the Swiss Federal Statistical Office 
(www.bfs.admin.ch) and calculated by multiplying the length of stay by the average daily costs. 
Indirect costs for gainfully employed patients prior to aSAH were calculated according to the 
human capital approach as reported previously 8. For productivity losses due to sick leave, the 
mean gross income given by the Swiss Federal Statistical Office (www.bfs.admin.ch) was 
divided by 365 days and then multiplied by the days of hospitalization and rehabilitation. In 
patients with failure to return to work, additional productivity losses were added for the time 
until the 65th birthday, which is the official retirement age in Switzerland. In patients with 
incomplete work recovery, productivity losses were adjusted to the percentage of reduced 
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Baseline characteristics, outcome scores, return to work, and health-related costs were analyzed 
separately for low-grade aSAH (WFNS 1-3) and high-grade aSAH (WFNS 4-5). For statistical 
analysis the outcome was dichotomized into favorable (GOSE 5-8) and unfavorable outcome 
(GOSE 2-4). Data are presented as median with interquartile range (IQR) or mean with 95% 
confidence interval (CI) where applicable. Differences between groups were compared using 
the Mann-Whitney U Test or Fisher test. To evaluate the cost-effectiveness, we calculated the 
effective costs per patient with favorable outcome (GOSE 5-8), defined as the costs for all 
patients divided by the number of independent patients as previously reported 13. Statistical 




Patient characteristics are shown in Table 2. Of the 150 patients, 42 had high-grade and 108 
low-grade aSAH. High-grade aSAH was significantly more often associated with Fisher 3 and 
4 bleedings, posterior circulation aneurysms, rescue therapies, and longer stay in the intensive 
care unit, neurosurgical ward and rehabilitation unit. The GOS at 3 and 12 months after aSAH 
as well as long-term follow-up was lower after high-grade compared to low-grade aSAH. Age, 
gender, employment status, aneurysm treatment modality and disposition after hospital 
discharge were comparable between both groups. The median time interval between aSAH and 




Functional Outcome  
The distribution of GOS (Figure 2) was significantly different when comparing 3-months and 
12-months follow-up (p<0.001), but there was no difference comparing 12-months and long-
term follow-up (p=0.684). The percentages of individual changes in GOS between 12 months 
and long-term follow-up are shown in Figure 3. GOS improvements were recorded in 1 of 38 
patients (2%) at 3 years, 3 of 42 patients (7%) at 4 years and 6 of 20 patients (22%) at 5 years 
after aSAH. A decline in GOS was observed in 1 of 38 patients (3%) at 2 years, 3 of 42 patients 
(7%) at 3 years, and 1 of 20 patients (4%) at 5 years after aSAH. Functional outcome according 
to the GOSE scores at long-term follow-up is presented in Table 3. Overall median GOSE was 
7.0 (IQR 5.0-7.0) and favorable outcome (GOSE 5-8) was achieved in 114 of 150 patients 
(76%). Thirty-five patients (23%) were severely disabled (GOSE 3-4) and 1 patient (1%) in a 
condition of unconsciousness (GOSE 2). High-grade compared to low-grade aSAH was 
associated with significantly less favorable outcome according to GOSE 5-8 (52% versus 85%, 
p<0.001).  
 
Return to Work 
Work recovery is presented in Table 4. In the group of 98 patients who were employed prior to 
aSAH (mean age 50 ± 9 years), 61 (62%) reported work recovery. Complete work recovery 
was achieved in 36 patients (37%) with a mean age of 47 ± 9 years. In the group with incomplete 
work recovery (mean age 47 ± 10 years), all patients were working fewer weekly hours with a 
mean proportional reduction from 86 ± 19% to 48 ± 19% (p<0.001). Of the 28 patients (29%) 
not returning to work (mean age 51 ± 6 years), 24 (86%) were unemployed due to aSAH-related 
health problems, 3 (11%) were looking for employment with a reduced workload and 1 (3%) 
had stopped working to take care of household and family. There was no difference in time to 
follow-up between 61 patients who returned to work fully or partially and those 28 patients 
with failure to return to work (2.6 years (range 1.3 – 4.6) versus 3.1 years (range 1.5 – 4.6); 
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p=0.1). Early retirement was reported in 9 patients (mean age 64 ± 4 years). Overall, work 
recovery was less frequent in high-grade compared to low-grade aSAH (39% versus 69%; 
p=0.013).  
 
Health Care Costs  
The costs per patient and total costs are shown in Table 5. The average costs per patient were 
calculated at € 344.277 (95% CI 268.383 to 420 171). Indirect costs accounted for 84% of total 
costs per patient and were mainly due to failure to return to work (66%). Per patient costs for 
acute in-hospital treatment were € 33.220, which made up for 59% of total direct costs. The 
absolute total costs were calculated at € 51.641.553.   
 
The costs per patient between high-and low-grade aSAH are depicted in Figure 3. Total costs 
per patient were greater for high-grade aSAH compared to low-grade aSAH (€ 422.496 (95% 
CI 258.489 to 586.503) versus € 329.193 (95% CI 242.142 to 416.244); p=0.039). The 
difference in direct costs between high-and low-grade was significant (€ 81.040 (95% CI 68.566 
to 93.515) versus € 46.055 (95% CI 41.500 to 50.610); p<0.001), but there was no significant 
difference in indirect costs between both groups (€ 341.456 (95% CI 178.923 to 503.988) versus 
€ 283.645 (95% CI 197.467 to 369.822); p=0.076). Effective costs per patient with favorable 
outcome (GOSE 5-8) were 2.1-fold greater for high-grade compared to low-grade aSAH (€ 
806.583 versus € 386.444).  
 
The costs per patient stratified by GOSE scores are shown in Figure 4. Total costs were greater 
in patients with GOSE 5-6 (€ 700.927 (95%CI 528.170 to 873.685)) compared to GOSE 7-8 (€ 
137.499 (95% CI 80.624 to 194.374); p<0.001) and GOSE 2-4 (€ 483.168 (95% CI 296.080 to 
670.256); p= 0.046). Direct costs increased successively with increasing degree of disability 
(GOSE 7-8: € 39.978 (95% CI 35.626 – 44.330); GOSE 5-6: € 57.878 (95% CI 47.477 to 
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68.310); GOSE 2-4: € 88.214 (95% CI 76.377 to 100.051) and indirect costs were greater in 
patients with GOSE 5-6 (€ 643.049 (95% CI 470.040 to 816.058) compared to GOSE 7-8 (€ 
40.562 (95% CI 10.349 to 70.774); p<0.001) and GOSE 2-4 (€ 394.954 (95% CI 207.094 to 




The study shows that favorable outcome after aSAH can be achieved in more than three-
quarters of survivors and nearly two-third report on work recovery in the long term. Favorable 
outcome is more frequent in low-grade (85%) compared to high-grade aSAH (52%). The total 
costs were € 344.277 per patient, which mainly accounted to indirect costs from productivity 
losses (84%). Acute in-hospital treatment was the main component of direct costs with an 
average of € 33.200 per patient. The total costs increase with increasing degree of disability and 
are greater for high-grade compared to low-grade aSAH. The effective costs per patient with 
favorable outcome is 2.1-fold greater for high-grade compared to low-grade aSAH.  
 
In the current era of aSAH management, treatment of high-grade aSAH is associated with 
favorable outcome in more than half of survivors in the long-term. Immediate initiation of 
neuroresuscitation in combination with early aneurysm occlusion resulted in good functional 
recovery in a considerable proportion of patients with high-grade aSAH 4,14. Recently, Schwartz 
et al. investigated functional recovery after high-grade aSAH and reported that 40 of 62 
survivors (65%) regain functional independence at 3 years after diagnosis 3. Outcome 
assessment beyond the first year after aSAH might be of particular importance, since delayed 
functional recovery has been reported in approximately 20% of high-grade aSAH patients 15. 
This was further corroborated by the findings of individual GOS improvements in our study.  
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In a consecutive cohort of aSAH patients, work recovery can be achieved in nearly two-thirds 
of survivors in the long-term. Up to date, only few studies reported on work recovery after 
aSAH 12,16. For low-grade aSAH patients with good functional recovery, Sonesson et al. found 
that 61 of 67 patients (91%) return to work at 25 years after aSAH 17. On the other hand, Passier 
et al. reported that 54 of 88 patients (61%) return to work if they were living at home at 3 years 
after aSAH 18. However, all previous studies on work recovery included patients who were 
independent and living at home. Thus, the results are difficult to interpret with regards to the 
general aSAH population, which also includes a significant number of patients who are partially 
or fully dependent and living in a nursing home or sheltered housing program. To the best of 
our knowledge, our study is the first investigation on work recovery in a consecutive cohort of 
high- and low-grade aSAH patients including all levels of functional recovery.  
 
Costs for aSAH rise considerably with increasing degree of disability in the long term. Despite 
the high level of resource use during acute hospital treatment, delayed ischemic neurological 
deficit (DIND) remains a major cause of poor outcome after aSAH. In a post-hoc analysis of 
the International Subarachnoid Hemorrhage Trial (ISAT), Rivero-Arias et al. showed that 
patients with DIND had a considerably increased hospital stay and fewer workdays at 2 years 
after aSAH 6. Consequently, there were substantial differences in costs for hospital treatment 
(€ 10.475) and productivity losses (€ 4.317) favoring patients without DIND. Unfortunately, no 
conclusions on cost-effectiveness can be drawn from the study because data on functional 
recovery are lacking. Indirect costs due to productivity losses after aSAH have been described 
in one other study 8. In this study, indirect costs per patient accounted for 41% (€ 15.800) of 
the total costs within the first year after aSAH (€ 38.300). Thus, so far data on long-term indirect 
costs due to productivity losses after aSAH were missing. In our cohort, indirect costs were 
greatest in patients with moderate disability (GOSE 5-6), who were independent but unable to 
return to their previous work fully or in part. In fact, indirect costs from productivity losses in 
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the long term (€288.426 per patient) made up for 84% of total costs (€344.277 per patient). On 
the other hand, direct costs from acute in-hospital and rehabilitation treatment are considerably 
less compared to the long-term health-economic consequences of failure to return to work or 
incomplete work recovery.  
 
The effective costs per patient with favorable outcome are substantially greater for high-grade 
aSAH compared to low-grade aSAH. Although several studies have identified the initial clinical 
presentation as the main cost-driving factor after aSAH 5,6,19, only one study reported on costs 
after high-grade aSAH more than 15 years ago 20. In this study, 64 of 148 high-grade aSAH 
patients (43%) were treated by either clipping (92%) or coiling (8%), the remaining patients 
were treated conservatively and died. Favorable outcome was achieved in 22 of 64 patients 
(34%) and the costs per favorable outcome were € 95.299. In recent decades, a marked shift 
towards treatment of higher severity in the aSAH population has been observed 21. Outcome 
improvements possibly reflect the major advances in aneurysm treatment modalities and 
extended resources in neurocritical care. Today, treatment of high-grade aSAH is associated 
with favorable outcome in more than half of survivors as shown by our results. However, 
treatment of high-grade aSAH is costly and possibly more than 2-fold greater compared to low-
grade aSAH if favorable outcome is achieved. Future advances in aSAH management aiming 
to prevent secondary brain injuries might decrease costs from productivity losses and thus affect 
the socioeconomic burden of aSAH beneficially.  
 
Our study has several limitations that need some considerations. Firstly, costs were calculated 
according to daily costs from hospitalization and productivity losses due to failure to return to 
work. Therefore, costs may have been underestimated because diagnostics, treatment costs, 
outpatient care, medications, potential out-of-pocket costs, household production impacts and 
caregiver time costs were not captured. These additional components might in fact account for 
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up to 20% of direct costs as suggested previously 8. Secondly, informed consent to participate 
in this study was not available for deceased patients or their relatives. The exclusion of non-
survivors (n=36) might lead to an underestimation of costs. Furthermore, selection bias may 
have occurred because not all patients responded to the mailed questionnaire or gave informed 
consent. However, a dropout rate of 12% (20 of 170 patients receiving mailed invitation to 
participate in the study) might be considered as acceptable. Finally, the single center design 




This study provides a first impression on long-term outcome, work recovery and costs in a 
consecutive cohort of high- and low-grade aSAH patients including all levels of functional 
recovery. Future multicenter studies are needed to understand the true economic burden of 
aSAH on society and patients. Because long-term disability and high-grade aSAH are important 
sources of rising costs after aSAH, there is an ongoing need to further improve management 
strategies for early detection and prevention of secondary brain injuries associated with 
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Figure 1: Flow chart of the study population and follow-up 
 
Figure 2: Distribution of Glasgow Outcome Scale (GOS) scores at 3- and 12-months as well 
as long-term follow-up after aneurysmal subarachnoid hemorrhage (aSAH) 
 
Figure 3: Percentage of individual changes in Glasgow Outcome Scale (GOS) between 12 
months and long-term follow-up after aneurysmal subarachnoid hemorrhage (aSAH)  
 
Figure 4: Total costs (A), direct costs (B) and indirect costs (C) per patient between high- and 
low-grade aneurysmal subarachnoid hemorrhage (aSAH)  
 
Figure 5: Total costs (A), direct costs (B) and indirect costs (C) per patient stratified by 













Table 1: Glasgow Outcome Scale (GOS) and Glasgow Outcome Scale Extended (GOSE) 
 





Resumption of normal life 
 
7 GR- 
 Minor disability due to neurological or psychological 
deficits  




 Disability and deficits of cognition or personality  




 Disability and deficits of cognition or personality  
Independent at home but unable to work 








 Fully dependent with someone around most of the 
time 





Condition of unconsciousness  







GOS, Glasgow Outcome Scale; GOSE, Glasgow Outcome Scale-Extended; GR, good recovery; MD, 
















     
Age in years; mean (SD) 55 (24-81) 56 (34-78) 54 (24-81) 0.5 
Female sex; n (%) 98 (65) 31 (65) 67 (62) 0.2 
Employed prior to aSAH 
     Professional Position 
     Support position 

















Fisher Score; n (%) 
     Fisher 1-2 












Aneurysm location; n (%) 
     Anterior circulation 












Aneurysm treatment modality; n (%) 
     Endovascular coiling 












Rescue Therapy; n (%) 
     Decompressive Craniectomy 
     Barbiturate Coma 

















Discharge destination; n (%) 
     Home 
     Rehabilitation Unit 

















Length of stay in days, median (IQR)     
     Intensive Care Unit  
     Neurosurgical Ward 
     Rehabilitation Unit 
17 (15-29) 











Glasgow Outcome Score, median (IQR)     
     3-months after aSAH 











Table 3: Outcome after aneurysmal subarachnoid hemorrhage (aSAH) at long-term follow-up 
 
Glasgow Outcome Scale 
Extended (GOSE); n (%) 
All Patients 
(n=150) 
High-grade      
aSAH (n=42) 
Low-grade       
aSAH (n=108) 
    
GOSE 8 34 (23) 8 (19) 26 (24) 
GOSE 7 44 (29) 6 (14) 38 (35) 
GOSE 6 26 (17) 5 (12) 21 (19) 
GOSE 5 10 (7) 3 (7) 7 (7) 
GOSE 4 16 (11) 8 (19) 8 (7) 
GOSE 3 19 (13) 11 (26) 8 (7) 
GOSE 2 1 (1) 1 (1) 0 (0) 
Favorable Outcome (GOSE 5-8) 114 (76) 22 (52) 92 (85) 
Unfavorable Outcome (GOSE 2-4) 36 (24) 20 (48) 16 (15) 






Table 4: Work recovery after aneurysmal subarachnoid hemorrhage (aSAH) at long-term follow-up 
 







    
Complete work recovery 36 (36) 5 (22) 31 (41) 
Incomplete work recovery 25 (26) 4 (17) 21 (28) 
No return to work 28 (29) 10 (44) 18 (24) 
Early retirement after aSAH 9 (9) 4 (17) 5 (7) 





Table 5: Costs per patient and total costs in Euro (€) after aneurysmal subarachnoid hemorrhage  
 
 Mean 95% CI Minimum Maximum Total 
Direct Costs       
    Acute in-hospital treatment (n=150) 33 220 33 772 – 35 667 8 928 111 600 4 982 940 
    Rehabilitation treatment (n=131) 20 056 16 908 – 23 204 0 117 480 2 928 200 
    Re-Hospitalization #1 (n=29) 3 181 1 800 - 4561 0 46 872 381 672 
    Re-Hospitalization #2 (n=8) 757 218 – 1 297 0 16 740 84 816 
Indirect Costs      
    Sick leave (n=98) 8 559 7 088 – 10 029 0 56 034 1 283 789 
    Early retirement (n=9) 10 158 2 301 – 18 016 0  338 289 1 523 758 
    Incomplete work recovery (n=25) 80 433  44 610 – 116 255 0  1 433 186 12 064 910 
    Failure to return to work (n=28) 189 276 117 954 – 260 599 0  1 999 320 28 391 468 
      
Total direct costs (n=150) 55 851 50 440 – 61 262 8 928 204 168 8 377 628 
Total indirect costs (n=150) 288 426 213 551 – 363 302 0 2 066 819 43 263 925 
Total costs (n=150) 344 277 268 383 – 420 171 16 000 2 036 855 51 641 553 
 
